Science 37 Holdings, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020
Assets
Current assets:
Cash and cash equivalents
Prepaid expenses
Restricted cash
Accounts receivable and unbilled services, net
Prepaid expenses and other current assets
Total current assets
Cash held in Trust Account
Property and equipment, net
Operating lease right-of-use assets
Capitalized software, net
Other assets
Total assets
Liabilities, preferred stock and stockholders’ equity
Current liabilities:
Accrued expenses
Accounts payable and accrued expenses
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Total current liabilities
Non-current liabilities:
Deferred revenue
Operating lease liabilities
Commissions payable
Other long-term liabilities
Long-term earn-out liability
Total liabilities
Preferred stock
Preferred stock, $0.0001 par value; 100,000,000 shares authorized, 0 issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Stockholders’ equity:
Common stock, $0.0001 par value; 400,000,000 shares authorized, 119,118,653 and 116,432,029 issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity
Total liabilities, preferred stock and stockholders’ equity

Comments